Novartis CEO Calms Concerns Over Zolgensma launch

The Swiss major has posted a strong set of financials for the second quarter and Vas Narasimhan is pleased with the roll-out of Zolgensma, Mayzent and Piqray.

Launch
Three key launches have gone as planned, the Swiss major claims • Source: Shutterstock

Novartis AG is keeping quiet when it comes to specific sales of its gene therapy Zolgensma but CEO Vas Narasimhan has said that contrary to some analyst claims, the launch is going well.

There is huge interest in Zolgensma (onasemnogene abeparvovec), which was approved in the US for all three types of spinal...

More from New Products

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.